Pharmaceuticals
U.S. Food & Drug Administration (FDA) Approves Investigational New Drug (IND) Application for Myrio's Lead Product (PHOX2B PC-CAR T) for the Treatment of Neuroblastoma
MELBOURNE, Australia, June 13, 2025 /PRNewswire/ -- On 7 May 2025, the FDA approved an IND application enabling Myrio's lead product (PHOX2B PC-CAR T) to enter human trials. Myrio, in collaboration the leading children's hospital in Philadelphia have co-developed a Chimeric Antigen Receptor (CAR-T...
2025-06-13 19:35
3125
PharmaResearch Spin-Off into Holding and Aesthetics Companies Approved by Board of Directors
SEONGNAM, South Korea, June 13, 2025 /PRNewswire/ -- PharmaResearch announced on June 13 that its board of directors has approved a corporate spin-off, resulting in the formation of two distinct entities: PharmaResearch Holdings, which will remain as the surviving entity focused on investment and ...
2025-06-13 14:21
2748
Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA's 85th Scientific Sessions
SAN FRANCISCO and SUZHOU, China, June 12, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...
2025-06-13 09:00
2596
Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions
SINGAPORE, June 12, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the expansion of its existing supply and distribution agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), to la...
2025-06-13 00:01
2808
Nona Biosciences and Visterra Partner to Advance Next-Generation Biotherapeutics for Immune-Mediated and Autoimmune Diseases
CAMBRIDGE, Mass., June 12, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I TM), today announced a license agreement with Visterra, Inc. to advance Visterra's next-generation biotherapeutic pipeline for immune-mediated ...
2025-06-12 20:03
2211
Dizal Showcases Two First-in-Class Therapies in Hematologic Malignancies at EHA and ICML 2025
* Golidocitinib demonstrated promising efficacy in maintaining and enhancing tumor response in peripheral T-cell lymphoma (PTCL) post first-line therapy with a 24-month disease-free survival (DFS) rate of 74.2% * DZD8586 exhibited significant antitumor activity in heavily pretreated chronic l...
2025-06-12 18:13
2388
Fapon Biopharma to Showcase Differentiated Pipeline, Including Phase 1 Immunocytokine FP008, and Innovative Technology Platforms at BIO 2025
BOSTON, June 12, 2025 /PRNewswire/ -- Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies and fusion proteins, is pleased to announce its participation in the BIO International Convention 2025 (BIO 2025), taking placeJune 16-19 in Boston Convention & Exhibition Cen...
2025-06-12 15:39
2209
Energenesis Biomedical to Unveil Promising Parkinson's Disease Therapy, ENERGI-F705PD, at BIO International 2025
TAIPEI, June 11, 2025 /PRNewswire/ -- Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biotechnology company pioneering cellular energy restoration therapeutics, today announced its participation in the BIO International Convention 2025, taking placeJune 16–19 in Boston, MA. The c...
2025-06-11 15:58
2203
Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics
- The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical's drug discovery programs for the generation of small molecule drugs. SEOUL, South Korea, June 11, 2025 /PRNewswire/ -- ...
2025-06-11 12:00
3792
Insilico Medicine Launches Nach01 Foundation Model on AWS Marketplace to Help Accelerate Generative Chemistry Innovation
CAMBRIDGE, Mass., June 10, 2025 /PRNewswire/ -- Insilico Medicine
2025-06-10 21:00
2760
ImmVira Announces First Patient Dosed in a Multi-Regional Phase II Clinical Trial Evaluating MVR-T3011 Oncolytic Immunotherapy in Patients with BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
SUZHOU, China, June 10, 2025 /PRNewswire/ -- ImmVira, a global leading clinical-stage biotechnology company focused on the development of next-generation novel oncolytic immunotherapy for treatment of cancer, announced that the first patient diagnosed with NMIBC has been dosed in a multi-regiona...
2025-06-10 20:00
3206
Sanyou Biopharmaceuticals and Medicovestor, Inc. Forge Strategic Partnership to Develop First-in-Class Chemoimmunotherapy Antibody-Drug Conjugates
SHANGHAI and NEW YORK, June 10, 2025 /PRNewswire/ -- Sanyou Biopharmaceuticals, a leadingShanghai-based high-tech biopharmaceutical company specializing in biologics R&D today announced the signing of a strategic cooperation agreement with Medicovestor, Inc., aNew York-based biotechnology company...
2025-06-10 18:00
2781
Caliway to Present First Preclinical Data on CBL-514 for GLP-1 Weight Rebound Management at BIO 2025
* Caliway to deliver a corporate presentation on June 17 at the BIO International Convention 2025, the world's largest biotech industry event. * For the first time at an international conference, Caliway will share preclinical results on CBL-514's potential new indication: combined withGLP-1 ...
2025-06-10 16:15
3270
Abbisko Therapeutics Announces China NMPA Acceptance of New Drug Application for Pimicotinib for the Treatment of TGCT
SHANGHAI, June 10, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (02256.HK) today announced that the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for pimicotinib, a highly selective, small-molecule CSF-1R inhibitor, as a Class 1 innovati...
2025-06-10 12:02
5809
VivaVision Announces Positive Comments from FDA for the Type C Meeting Regarding VVN461LD for Post-operative Infalmmation - Agreeing the Phase 2 Trial to Be Served as One of the Two Pivotal Studies.
HONG KONG and WENZHOU, China, June 9, 2025 /PRNewswire/ -- VivaVision Biotech (VivaVision), a late clinical-stage, privately-held biotech company focused on developing innovative ophthalmic drugs, announced today that it received written preliminary comments for the Type C meeting to be held in e...
2025-06-10 00:00
2259
Eluminex Biosciences Announces Phase 1b Single Ascending Dose Study Results of a Novel Pentavalent Trispecific Fusion Antibody (EB-105) in Patients with Diabetic Macular Edema (DME)
* EB-105 Targets VEGF-A, -B, PlGF, Ang-2, and IL-6R * Improvements in Visual Acuity and Retinal Edema Observed at All Dose Levels * No Safety Issues Observed Following a Single Intravitreal (IVT) Injection * Multiple Ascending Dose Study Planned for Q3 2025 in DME MOUNTAIN VIEW, Calif., J...
2025-06-10 00:00
2508
World's First HLA-G Targeted Exosome Therapy for Cancer Enters U.S. Clinical Trials
FDA Greenlights SOB100 for Phase I; Breakthrough Study Published in Nature Communications TAICHUNG, June 9, 2025 /PRNewswire/ -- A research team led by Dr. Der-Yang Cho, Superintendent of China Medical University Hospital (Taiwan), in collaboration with Shine-On Biomedical Co., has developed the...
2025-06-09 20:03
2503
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
TAIPEI, June 9, 2025 /PRNewswire/ -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, andTaiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW), today announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial rights for BYQLOVI™ ...
2025-06-09 19:00
4201
Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA)
HONG KONG, June 8, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that poster presentations on preliminary studies of its oral small moleculeGLP-1 Receptor (GLP-1R) agonist ASC30 and adipose-targeted, muscle-preserving weight loss drug candidate ASC47 will be present...
2025-06-09 08:15
2362
BIOSeedin Innovation Partnering Conference 2025: Spotlight on China's Biopharma Trailblazers and Global Collaboration
NEWARK, Del., June 5, 2025 /PRNewswire/ -- China's influential innovative drug asset cooperation platform BIOSeedin Innovation Partnering Conference (BIOS), established in 2021, has quickly become one of the most prestigious biopharmaceutical partnering events in APAC. Hosted annually by bioSeed...
2025-06-06 01:00
4598
Week's Top Stories
Most Reposted
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 303 media titles]
2026-05-21 22:13
The Philippines Sets a New Standard in Muslim-Friendly Tourism
[Picked up by 287 media titles]
2026-05-26 10:30
Agoda and Philippines Department of Tourism announce strategic partnership to promote and elevate tourism
[Picked up by 285 media titles]
2026-05-27 09:16
ISDN's IDI Dynamics debuts high-speed laser marker for semiconductor assembly and test (OSAT)
[Picked up by 280 media titles]
2026-05-26 08:40
Consistently recognised: Infobip named a Leader in Gartner® Magic Quadrant™ for CPaaS again
[Picked up by 279 media titles]
2026-05-21 16:31
Most Read
NYSE Content Update: Lincoln International Pops by 13% in First Day of Trade
2026-05-21 21:04
8783
Scienjoy Holding Corporation Reports Unaudited First Quarter 2026 Financial Results
2026-05-21 20:30
8477
